Cyrus Therapeutics
Drugging the undruggable targets
Drugging the undruggable targets
Cyrus Therapeutics is a promising biotechnology company that was founded in 2019 in South Korea. The company's mission, 'drugging the undruggable targets,' emphasizes its dedication to developing innovative medicines for chronic or life-threatening diseases with high unmet needs. Utilizing small molecule drugs and new chemical modalities such as targeted protein degraders, Cyrus Therapeutics is at the forefront of providing solutions for challenging medical conditions. The recent KRW29.00B Series B investment raised on 27 January 2022, with participation from notable investors including Mirae Asset Venture Investment, GC Pharma, Mirae Asset Capital, Timefolio Asset Management, Paratus Investment Inc., Kolon Investment, and Atinum Partners, signifies strong confidence in the company's potential. With its focus on tackling previously considered 'undruggable' targets, Cyrus Therapeutics is positioned as an influential player in the biotechnology and pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | KRW29.00B | 7 |
|
27 Jan 2022 |
| Series A | KRW10.00B | 3 |
|
29 Sep 2020 |
No recent news or press coverage available for Cyrus Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.